Welcome to our dedicated page for STERIS plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc President and CEO Daniel A. Carestio reported a routine tax-withholding transaction related to vesting restricted stock. On June 3, 2026, 2,619 ordinary shares were withheld at $210.19 per share to cover employment and tax obligations when 5,937 restricted shares vested.
After this withholding, he directly owned 69,964 ordinary shares, including 44,176 restricted shares as of June 3, 2026. These restricted shares are scheduled to lapse in stages between June 4, 2026 and June 4, 2029.
STERIS plc Senior Vice President and CFO Karen L. Burton reported an automatic share disposition tied to tax withholding. On June 3, 2026, 190 ordinary shares were withheld from 651 restricted shares that vested, using the NYSE closing price of $210.19 per share to determine the tax value. This was not an open‑market sale but a payment of taxes in shares.
After this transaction, Burton directly holds 13,274 ordinary shares, of which 9,588 remain restricted as of June 3, 2026. Those restricted shares are scheduled to lapse in stages between June 4, 2026 and June 4, 2029.
STERIS plc insider files Form 144 to sell shares. Director or reporting person Daniel A. Carestio reported transactions tied to equity compensation. The filing lists 1,374 shares associated with a restricted stock lapse on 06/02/2026 and shows 3,054 shares sold during the prior three months on 06/04/2026 for $655,511.00.
STERIS plc senior vice president and general counsel John Adam Zangerle reported routine equity compensation activity and related tax withholding. On June 2, 2026, 247 ordinary shares were withheld to cover taxes on 846 restricted shares that vested, reflecting a tax-withholding disposition rather than an open-market sale.
The same day, he received 4,359 ordinary shares as a grant at no cost and was granted employee stock options for 15,200 ordinary shares with a $230.74 exercise price, vesting in four annual installments from 2027 through 2030 and expiring on June 2, 2036. Following these awards, he directly holds 37,444 ordinary shares, of which 10,867 are restricted as of June 2, 2026.
STERIS plc executive Renato Tamaro, Vice President & Corporate Treasurer, reported routine equity compensation changes. He received 750 ordinary shares as a grant and a new employee stock option for 2,620 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036. To cover tax obligations on previously granted restricted stock, 41 shares were withheld from 141 restricted shares that vested on June 2, 2026, a tax-withholding disposition rather than an open-market sale. Following these transactions, Tamaro holds 6,323 ordinary shares directly, of which 1,843 shares are restricted as of June 2, 2026 and scheduled to vest in tranches between June 3, 2026 and June 4, 2029.
STERIS plc VP Lindsey McGowan reported routine equity compensation changes. On June 2, 2026, 1,128 restricted ordinary shares vested, and 329 shares were withheld at $209.76 per share to cover tax obligations, leaving 5,656 ordinary shares held directly.
McGowan also received a new grant of 1,155 ordinary shares, increasing direct holdings to 5,985 shares, of which 3,117 are restricted as of June 2, 2026. In addition, she was granted 4,036 employee stock options exercisable at $230.74 per share, expiring on June 2, 2036, vesting in four equal annual installments starting in 2027.
Separately, 255 ordinary share equivalents are held for her account under the STERIS Corporation 401(k) Plan as of May 29, 2026. These transactions reflect compensation grants and tax withholding rather than open-market buying or selling.
STERIS plc senior executive Cary L. Majors reported routine equity compensation and related tax withholding. On June 2, 2026, he received a grant of 4,746 ordinary shares, bringing his direct holdings to 17,405 shares. A separate entry shows 67 shares disposed at $209.76 per share solely to satisfy tax obligations on 2,140 restricted shares that vested the same day.
Majors was also granted an employee stock option for 16,548 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036. As of June 2, 2026, 10,047 of his ordinary shares are restricted, scheduled to vest in stages through June 4, 2029. In addition, units representing 67 ordinary share equivalents are held for him under the STERIS Corporation 401(k) Plan.
STERIS plc senior vice president Julia Madsen reported routine equity compensation activity. She received 2,316 ordinary shares as a stock award and a new employee stock option covering 8,080 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036. To cover tax obligations on 352 restricted shares that vested on June 2, 2026, 127 shares were withheld by the company, which is recorded as a tax-withholding disposition rather than an open-market sale. After these transactions, she holds 12,691 ordinary shares directly, of which 5,398 are restricted shares scheduled to vest in tranches between June 2026 and June 2029.
STERIS plc senior executive Kenneth E. Kohler reported routine equity compensation and related tax withholding. He received 2,199 ordinary shares as a grant and 7,668 employee stock options to buy ordinary shares at $230.74 per share, expiring on June 2, 2036.
The filing also shows 66 ordinary shares valued at $209.76 each were withheld to cover taxes on 225 restricted shares that vested on June 2, 2026, rather than sold in the market. After these transactions, he directly holds 11,666 ordinary shares, including 5,115 restricted shares that vest in stages through June 4, 2029.
STERIS plc SVP & Chief HRO Mary Clare Fraser reported equity awards on June 2, 2026. She received a grant of 10,492 employee stock options with an exercise price of 230.74 per share, vesting in four annual tranches from 2027 to 2030 and expiring in 2036. She also acquired 3,009 ordinary shares, while 591 shares were withheld at 209.76 per share to cover tax obligations on 2,028 restricted shares that vested. After these transactions she directly holds 14,627 ordinary shares, of which 7,554 remain restricted with scheduled lapses between 2026 and 2029.